Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

ANI Pharmaceuticals Forecasts 2024 Net Revenue Of $540M-$560M Versus Prior Guidance Of $520M-$542M And Consensus Of $554.598M, With Cortrophin Gel Revenue Of $185M-$195M Compared To Prior Guidance Of $170M-$180M

Author: Benzinga Newsdesk | August 06, 2024 07:01am

Posted In: ANIP